Abstract |
Aberrant expression of the transcription factor ERG is a key driving event in approximately one-half of all of prostate cancers. Lacking an enzymatic pocket and mainly disordered, the structure of ERG is difficult to exploit for therapeutic design. We recently identified EWS as a specific interacting partner of ERG that is required for oncogenic function. In this study, we aimed to target this specific protein- protein interaction with small molecules. A high-throughput screening (HTS) strategy was implemented to identify potential protein- protein interaction inhibitors. Secondary assays verified the function of several hit compounds, and one lead compound inhibited ERG-mediated phenotypes in prostate cells. This is the first study aimed at targeting the ERG- EWS protein- protein interaction for the development of a small molecule-based prostate cancer therapy.
|
Authors | Taylor R Nicholas, Jingwei Meng, Benjamin M Greulich, Teresa Stevie Morris, Peter C Hollenhorst |
Journal | PloS one
(PLoS One)
Vol. 15
Issue 9
Pg. e0238999
( 2020)
ISSN: 1932-6203 [Electronic] United States |
PMID | 32915889
(Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, Non-U.S. Gov't)
|
Chemical References |
- ERG protein, human
- EWSR1 protein, human
- RNA-Binding Protein EWS
- Recombinant Proteins
- Small Molecule Libraries
- Transcriptional Regulator ERG
|
Topics |
- Cell Line, Tumor
- Drug Screening Assays, Antitumor
(methods)
- Feasibility Studies
- High-Throughput Screening Assays
(methods)
- Humans
- Male
- Prostatic Neoplasms
(drug therapy, genetics, metabolism)
- Protein Interaction Domains and Motifs
(drug effects)
- RNA-Binding Protein EWS
(antagonists & inhibitors, genetics, metabolism)
- Recombinant Proteins
(drug effects, genetics, metabolism)
- Small Molecule Libraries
- Transcriptional Regulator ERG
(antagonists & inhibitors, genetics, metabolism)
|